Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...
Fintel reports that on December 6, 2024, BMO Capital initiated coverage of Protagonist Therapeutics (NasdaqGM:PTGX) with a Outperform recommendation. As of December 3, 2024, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results